The R&D productivity challenge: transforming the pharmaceutical ecosystem.
Uloženo v:
| Název: | The R&D productivity challenge: transforming the pharmaceutical ecosystem. |
|---|---|
| Autoři: | Schuhmacher A; Technische Hochschule Ingolstadt, Germany; University of St Gallen, Switzerland. Electronic address: alexander.schuhmacher@thi.de., Gassmann O; University of St Gallen, Switzerland., Kwisda S; EY Parthenon Strategy & Transactions, Zurich, Switzerland., Kremer M; EY Parthenon Strategy & Transactions, Berlin, Germany., Hinder M; Novartis, Basel, Switzerland; University of Zurich, Switzerland., Hartl D; University of Tübingen, Germany; Granite Bio, Basel, Switzerland. |
| Zdroj: | Drug discovery today [Drug Discov Today] 2025 Nov; Vol. 30 (11), pp. 104494. Date of Electronic Publication: 2025 Oct 09. |
| Způsob vydávání: | Journal Article; Review |
| Jazyk: | English |
| Informace o časopise: | Publisher: Elsevier Science Ltd. Country of Publication: England NLM ID: 9604391 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5832 (Electronic) Linking ISSN: 13596446 NLM ISO Abbreviation: Drug Discov Today Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Kidlington, Oxford : Irvington, NJ : Elsevier Science Ltd. ; Distributed by Virgin Mailing and Distribution, c1996- |
| Výrazy ze slovníku MeSH: | Drug Industry*/organization & administration , Drug Industry*/economics , Drug Industry*/trends , Research*/economics , Research*/organization & administration, Humans ; Biotechnology ; Efficiency, Organizational |
| Abstrakt: | The persistent decline in pharmaceutical R&D productivity has been extensively analyzed and debated for over two decades, with profound implications for the structure and strategy of the pharmaceutical industry. This systemic challenge forced many leading companies to adapt their R&D models, influencing internal capabilities and external innovation strategies. In response, the industry has evolved into a complex, interdependent biopharmaceutical ecosystem encompassing large pharmaceutical corporations, biotech innovators and specialized service providers. Although R&D productivity affects all research-driven companies, its consequences are particularly pronounced for large pharmaceutical firms, because the scale and capital intensity of their R&D activities make productivity a crucial determinant of long-term competitiveness and sustainability. By contrast, other stakeholders are only partially adversely affected, whereas some can even obtain value from it. (Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.) |
| Contributed Indexing: | Keywords: Pharmaceutical industry; R&D efficiency; R&D productivity; blockbuster; business model; drug discovery; research and development |
| Entry Date(s): | Date Created: 20251009 Date Completed: 20251120 Latest Revision: 20251120 |
| Update Code: | 20251121 |
| DOI: | 10.1016/j.drudis.2025.104494 |
| PMID: | 41067368 |
| Databáze: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | The persistent decline in pharmaceutical R&D productivity has been extensively analyzed and debated for over two decades, with profound implications for the structure and strategy of the pharmaceutical industry. This systemic challenge forced many leading companies to adapt their R&D models, influencing internal capabilities and external innovation strategies. In response, the industry has evolved into a complex, interdependent biopharmaceutical ecosystem encompassing large pharmaceutical corporations, biotech innovators and specialized service providers. Although R&D productivity affects all research-driven companies, its consequences are particularly pronounced for large pharmaceutical firms, because the scale and capital intensity of their R&D activities make productivity a crucial determinant of long-term competitiveness and sustainability. By contrast, other stakeholders are only partially adversely affected, whereas some can even obtain value from it.<br /> (Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.) |
|---|---|
| ISSN: | 1878-5832 |
| DOI: | 10.1016/j.drudis.2025.104494 |